Granules Life Sciences receives USFDA approval for its Hyderabad unit

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

27 November 2025 15:10:00

Adani Ports

1509.00

(0.21%)

Asian Paints

2879.80

(0.17%)

Axis Bank

1286.65

(-0.27%)

Bajaj Finance

1033.10

(2.21%)

Bajaj Finserv

2101.75

(0.86%)

Bharat Electro..

413.10

(-0.47%)

Bharti Airtel

2116.60

(-0.49%)

Eternal Ltd

302.90

(-1.27%)

HCL Technologi..

1629.30

(0.71%)

HDFC Bank

1008.80

(0.49%)

Hind. Unilever

2453.60

(1.16%)

ICICI Bank

1393.10

(1.32%)

Infosys

1566.20

(0.54%)

ITC

404.05

(0.45%)

Kotak Mah. Ban..

2109.55

(0.30%)

Larsen & Toubr..

4083.50

(0.55%)

M & M

3681.30

(-0.11%)

Maruti Suzuki

15900.00

(-1.58%)

NTPC

327.05

(0.25%)

Power Grid Cor..

273.70

(-0.49%)

Reliance Indus..

1564.05

(-0.36%)

SBI

972.45

(-1.18%)

Sun Pharma.Ind..

1810.10

(0.29%)

Tata Motors PV..

357.80

(-0.39%)

Tata Steel

168.00

(-1.03%)

TCS

3136.25

(-0.82%)

Tech Mahindra

1511.75

(-0.55%)

Titan Company

3902.85

(0.16%)

Trent

4265.00

(-0.63%)

UltraTech Cem.

11625.90

(-1.14%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Granules Life Sciences receives USFDA approval for its Hyderabad unit	Share Back
(11 Nov 2025)
Granules India today announced that its wholly owned subsidiary, Granules Life Sciences(GLS), located in Hyderabad (FEI: 3030495702), has received U.S. Food and Drug Administration (FDA) approval for a product that was the subject of a Pre Approval Inspection (PAI) conducted between 28 July and 01 August 2025. There was one observation during that inspection, and the GLS had submitted its response within the stipulated time. With this approval, the GLS facility is now deemed approved by the U.S. FDA, marking a major milestone for Granules India as it expands its finished dosage manufacturing capabilities. This is the first FDA approval for the GLS site. The company plans to launch the approved product in the U.S. market soon. The same product is already approved and manufactured at Granules' Gagillapur facility. The new approval will help strengthen market share and support business continuity through multi-site manufacturing.
Top